Payment overview · 2025
General Payments
$1,175.10
39 reported records · 15 companies
Healthcare provider profile · identity verified
Katrice L Herndon-Ogunleye, MD
Allopathic & Osteopathic Physicians|Internal Medicine · DETROIT, MI · NPI 1407969827
Verified facts
What the public records show
CMS Open Payments records show Katrice L Herndon-Ogunleye, MD received $1,175.10 in general payments during 2025 across 39 reported records.
AstraZeneca Pharmaceuticals LP accounted for 25.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Nurtec Odt, Ozempic, Rybelsus, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $301.93 | 25.7% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $171.21 | 14.6% | 8 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $164.30 | 14.0% | 3 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $113.25 | 9.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $93.55 | 8.0% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $61.60 | 5.2% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $59.89 | 5.1% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $46.59 | 4.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $40.06 | 3.4% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $37.73 | 3.2% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $26.36 | 2.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.34 | 1.5% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.42 | 1.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $13.47 | 1.1% | 1 | 2025 |
| VivaQuant Inc, dba Rhythm Express | Unresolved — no canonical attribution shown | $13.40 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,175.10 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $164.30 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $156.11 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $116.10 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $93.55 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $93.55 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $59.89 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $46.59 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $40.06 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $39.91 | 6 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $37.73 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $37.71 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $26.36 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $23.89 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.34 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.34 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $15.20 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.42 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $13.47 | 1 | 2025 |
Source payment records
|
|||||
| RHYTHM EXPRESS Normalized: rhythm express |
Device | VivaQuant Inc, dba Rhythm Express | $13.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 135 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 89 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 146 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
73 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
146 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
135 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
130 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
89 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 758 | 140 |
| Atorvastatin Calcium | Atorvastatin Calcium | 670 | 131 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 430 | 79 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 429 | 55 |
| Lisinopril | Lisinopril | 293 | 53 |
| Omeprazole | Omeprazole | 279 | 50 |
| Nifedipine Er | Nifedipine | 271 | 50 |
| Fluticasone Propionate | Fluticasone Propionate | 264 | 50 |
| Gabapentin | Gabapentin | 264 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 257 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 249 | 44 |
| Ibuprofen | Ibuprofen | 237 | 57 |
| Losartan Potassium | Losartan Potassium | 234 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 228 | 44 |
| Potassium Chloride | Potassium Chloride | 221 | 44 |
| Metformin Hcl | Metformin Hcl | 205 | 36 |
| Meloxicam | Meloxicam | 197 | 36 |
| Famotidine | Famotidine | 182 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 169 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 163 | 41 |
| Furosemide | Furosemide | 163 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 153 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 146 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 142 | 25 |
| Jardiance | Empagliflozin | 135 | 27 |
| Naproxen | Naproxen | 133 | 25 |
| Trulicity | Dulaglutide | 130 | 22 |
| Tramadol Hcl | Tramadol Hcl | 124 | 19 |
| Carvedilol | Carvedilol | 122 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 120 | 25 |
| Simvastatin | Simvastatin | 118 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 116 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 115 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 111 | 20 |
| Clobetasol Propionate | Clobetasol Propionate | 109 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 108 | 15 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 105 | 21 |
| Meclizine Hcl | Meclizine Hcl | 95 | 19 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 94 | 16 |
| Trazodone Hcl | Trazodone Hcl | 94 | 23 |
| Ventolin Hfa | Albuterol Sulfate | 94 | 27 |
| Fenofibrate | Fenofibrate | 93 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 92 | 13 |
| Metformin Hcl Er | Metformin Hcl | 92 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 91 | 19 |
| Hydrocortisone | Hydrocortisone | 90 | 25 |
| Levothyroxine Sodium | Levothyroxine Sodium | 90 | 18 |
| Clonazepam | Clonazepam | 89 | 12 |
| Ozempic | Semaglutide | 89 | 12 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 83 | 23 |
| Baclofen | Baclofen | 80 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 79 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 78 | 11 |
| Diazepam | Diazepam | 77 | 12 |
| Alendronate Sodium | Alendronate Sodium | 76 | 16 |
| Clonidine Hcl | Clonidine Hcl | 75 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 75 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 73 | 20 |
| Farxiga | Dapagliflozin Propanediol | 73 | 16 |
| Ketoconazole | Ketoconazole | 72 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 72 | 13 |
| Glipizide Er | Glipizide | 69 | 13 |
| Prednisone | Prednisone | 69 | 34 |
| Montelukast Sodium | Montelukast Sodium | 68 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 68 | suppressed |
| Allopurinol | Allopurinol | 67 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 67 | 20 |
| Spironolactone | Spironolactone | 66 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 65 | 12 |
| Lovastatin | Lovastatin | 65 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 65 | 12 |
| Fluconazole | Fluconazole | 63 | 24 |
| Linzess | Linaclotide | 62 | suppressed |
| Azithromycin | Azithromycin | 61 | 42 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 61 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 60 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 59 | 14 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 56 | suppressed |
| Valsartan | Valsartan | 56 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 53 | suppressed |
| Januvia | Sitagliptin Phosphate | 51 | 11 |
| Pregabalin | Pregabalin | 51 | suppressed |
| Eliquis | Apixaban | 49 | suppressed |
| Colchicine | Colchicine | 48 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 48 | 12 |
| Rybelsus | Semaglutide | 48 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 47 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 46 | suppressed |
| Atenolol | Atenolol | 45 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 14 |
| Chlorthalidone | Chlorthalidone | 44 | suppressed |
| Lactulose | Lactulose | 44 | 14 |
| Donepezil Hcl | Donepezil Hcl | 43 | suppressed |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Myrbetriq | Mirabegron | 42 | suppressed |
| Mounjaro | Tirzepatide | 41 | suppressed |
| Topiramate | Topiramate | 39 | suppressed |
| Levetiracetam | Levetiracetam | 38 | suppressed |
| Nystatin | Nystatin | 37 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | suppressed |
| Acyclovir | Acyclovir | 33 | suppressed |
| Entresto | Sacubitril/Valsartan | 33 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 32 | suppressed |
| Nitroglycerin | Nitroglycerin | 29 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 29 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 28 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Acarbose | Acarbose | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 24 | 17 |
| Ibandronate Sodium | Ibandronate Sodium | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Metronidazole | Metronidazole | 22 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Brilinta | Ticagrelor | 20 | suppressed |
| Cilostazol | Cilostazol | 20 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 11 |
| Leflunomide | Leflunomide | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Oxycontin | Oxycodone Hcl | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 15 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 15 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 14 | suppressed |
| Piroxicam | Piroxicam | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Minoxidil | Minoxidil | 13 | suppressed |
| Novolin R | Insulin Regular, Human | 13 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Fluocinolone Acetonide | Fluocinolone/Shower Cap | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Alprazolam | Alprazolam | 11 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Klor-Con 10 | Potassium Chloride | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Prezcobix | Darunavir/Cobicistat | 11 | suppressed |
| Scopolamine | Scopolamine | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,175.10 · 39 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, AUSTEDO XR, BEXSERO, BREZTRI, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, JARDIANCE, Korlym, NURTEC ODT, Ozempic, RHYTHM EXPRESS, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, Veozah, ZENPEP, ZORYVE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error